Hansoh Pharmaceutical Group Company Limited
3692
株式のランク
#916
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
株価
$4.36
時価総額
$26.43B
変化（1日）
-0.87%
変化（1年）
-5.62%
国
CN
取引 Hansoh Pharmaceutical Group Company Limited (3692)
カテゴリー
Healthcare
Hansoh Pharmaceutical Group Company Limited（3692）の利益
Jun 2026 時点の利益 TTM: $1.14B
Hansoh Pharmaceutical Group Company Limited の最新の財務報告によると、同社の現在の利益は $1.14B です。2023 年には $532.05M の利益を上げ、これは 2022 年の利益 $427.44M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Hansoh Pharmaceutical Group Company Limited の利益の推移（2016 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.14B | 63.74% |
| 2024 | $696.69M | 30.94% |
| 2023 | $532.05M | 24.47% |
| 2022 | $427.44M | -17.68% |
| 2021 | $519.22M | 9.48% |
| 2020 | $474.28M | 10.05% |
| 2019 | $430.96M | 28.37% |
| 2018 | $335.73M | 13.01% |
| 2017 | $297.07M | 14.31% |
| 2016 | $259.87M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 54.69% |
IN
|
